Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Sep 1, 2026 · Filed Sep 3, 2026
Moderna's Chief Legal Officer sold $486K of Moderna shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$485,766
Shares × reported transaction price
32 days after results of Jul 31, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $154.27 on Sep 1, 2026, 590% above its 52-week low and 12% below its high, after a 159% rise over the previous 30 trading days
52-week range $22.36 (Nov 20, 2025) to $174.38 (Aug 19, 2026), 87% of the way up, from 252 adjusted closes. 30 trading days earlier: $59.66 on Jul 21, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.1% | −0.8% | −0.3% |
| 30 days | +39.6% | +0.6% | +39.0% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$5.81M of Moderna
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.